Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor
Top Cited Papers
- 31 October 2003
- journal article
- other
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 302 (5646) , 875-878
- https://doi.org/10.1126/science.1087061
Abstract
Because of its requirement for signaling by multiple cytokines, Janus kinase 3 (JAK3) is an excellent target for clinical immunosuppression. We report the development of a specific, orally active inhibitor of JAK3, CP-690,550, that significantly prolongedsurvival in a murine model of heart transplantation and in cynomolgus monkeys receiving kidney transplants. CP-690,550 treatment was not associatedwith hypertension, hyperlipidemia, or lymphoproliferative disease. On the basis of these preclinical results, we believe JAK3 blockade by CP-690,550 has potential for therapeutically desirable immunosuppression in human organ transplantation andin other clinical settings.Keywords
This publication has 18 references indexed in Scilit:
- Suppression of early T-cell–receptor-triggered cellular activation by the Janus kinase 3 inhibitor WHI-P-154Transplantation, 2003
- What does it take to make a natural killer?Nature Reviews Immunology, 2003
- The Year in Review – ATC 2002American Journal of Transplantation, 2003
- A Critical Role for IL-21 in Regulating Immunoglobulin ProductionScience, 2002
- Control of T Cell Function by Positive and Negative RegulatorsScience, 2002
- Cytokine Signaling in 2002Cell, 2002
- Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemiaJournal of Clinical Investigation, 2000
- The Banff 97 working classification of renal allograft pathologyKidney International, 1999
- Mutation of Jak3 in a Patient with SCID: Essential Role of Jak3 in Lymphoid DevelopmentScience, 1995
- Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)Nature, 1995